Navigation Links
Vernalis and Paul Capital Healthcare Sign euro 18.4 Million Financing Agreement
Date:4/20/2008

NEW YORK and WINNERSH, England, April 21 /PRNewswire/ -- Paul Capital Healthcare and Vernalis plc (LSE: VER) today announced that they have signed a financing agreement relating to frovatriptan, Vernalis' product for the treatment of migraine. Under the agreement, Vernalis will receive approximately euro 18.4 million in cash from Paul Capital Healthcare and, in return, Paul Capital Healthcare will receive approximately 90 per cent of Menarini's payments to Vernalis under their exclusive license and supply agreement for the commercialization of frovatriptan in Europe and certain other territories. Vernalis will continue to supply Menarini with frovatriptan active pharmaceutical ingredient.

Frovatriptan is currently approved for the acute treatment of migraine in Europe, the United States, Canada and seven Central American countries.

"Earlier this year, Vernalis restructured its operations to focus on its innovative discovery programs and to advance its promising pipeline of development stage products to the point at which they can be partnered. This transaction with Paul Capital Healthcare secures significant, non-dilutive funds for Vernalis, giving us the platform to rebuild new shareholder value in the medium term," said Tony Weir, CFO, Vernalis.

Dr. Ken Macleod, a partner at Paul Capital Healthcare, said: "Migraine affects about 10 percent of people and leads to billions of dollars in lost productivity each year. After extensively evaluating both the clinical and commercial data for frovatriptan, we believe this drug is positioned to capture a growing share of the market for migraine therapies. Growth capital is the hallmark of the companies and products in which Paul Capital Healthcare invests, and provides a compelling rationale for adding our investment in Vernalis and frovatriptan to our portfolio of investments."

About Paul Capital Partners and Paul Capital Healthcare

Through its funds, Paul Capital Healthcare is one
'/>"/>

SOURCE Paul Capital Healthcare
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. SPO Medical Retains American Capital Ventures for Investor Relations Services
2. MichBio Will Host Workshop on Capital Formation Prior to April 22 Annual Meeting
3. CV Therapeutics Announces $185 Million Transaction with TPG-Axon Capital for Half of Royalty for Lexiscan(TM) (regadenoson) Injection
4. Powersafe Technology Corp. Recapitalizes, Executes Merger Agreement with Amplification Technologies, and Invests in Amplification
5. RiverVest Venture Partners(R), a St. Louis-Based Venture Capital Firm Focusing on Life Sciences, Closes on Fund II, Names John P. McKearn, Ph.D., Venture Partner
6. Biotech Avoids Fall Out From Tough Quarter for Capital Markets
7. Plethora and Paul Capital Healthcare sign a $25 million revenue interest financing agreement with an option for an additional $3 million equity investment
8. Vermillion Meets Minimum Bid Price and Receives NASDAQ Staff Determination Letter for Minimum Market Capitalization
9. Pharmasset Receives $10 Million of Working Capital
10. Alexza Completes $10 Million Equity Financing with Bio*One Capital to Initiate Commercial Manufacturing in Singapore
11. Insmed Announces Listing Transfer from Nasdaq Global Market to Nasdaq Capital Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... ST. LOUIS , June 2, 2015 /PRNewswire/ ... leading Life Science and Technology company, announced today ... XCell Science to launch genetically engineered human ... to advance the research of neurological diseases. These ... portfolio, provide unique and versatile tools for the ...
(Date:6/2/2015)... 02, 2015 Through rare discovery of ... Yancy Corporation is enabling World Scientists to actually ... biological sample, displaying the full nature (position, shape, size, ... , Jeff Porter, Co-Founder of the Yancy Corporation, says, ... – rare. They come once in a lifetime, if ...
(Date:6/1/2015)... YORK , June 1, 2015  Turing ... researcher  Eliseo Oreste Salinas , MD, MSc,  has ... development. Dr. Salinas, who holds a ... pharmacology, brings a record of significant accomplishments in ... psychiatry.  Dr. Salinas has played a ...
(Date:6/1/2015)... YORK , June 1, 2015 ... by the fermentation of sugar or cellulose. Bio-alcohols are ... can be used as a replacement for gasoline in ... grow at a CAGR of 9 percent over the ... The global bio-alcohols market can be segmented into five: ...
Breaking Biology Technology:Sigma-Aldrich to Launch XCell Science Genetically Engineered iPSC-Derived Neural Disease Cells 2Sigma-Aldrich to Launch XCell Science Genetically Engineered iPSC-Derived Neural Disease Cells 3Scientists Eying Rare Discovery Of New Physics & Light Microscope Technology 2Turing Pharmaceuticals Names Eliseo Salinas, MD and MSc, President of Research and Development 2Turing Pharmaceuticals Names Eliseo Salinas, MD and MSc, President of Research and Development 3Global Bio-alcohols Market 2015-2019 2
... ... ... var shortURL = ... need to grab the first one. for (var r in data.results) { first_result = data.results[r]; break; } for (var ...
... 2010 Kendle (Nasdaq: KNDL ), a ... business awards for the third quarter of 2010 of ... quarter moderated significantly to $10.4 million or 1.3 percent ... in a net book-to-bill of 1.5. New business authorizations ...
... DST Health Solutions, LLC, today launched new versions ... Advance, PowerMHC, PowerMHS and PowerSTEPP. The platforms now support ... & Medicaid Services (CMS). This change—from Version 4010/4010A to ... effective Jan. 1, 2012, as designated by CMS. ...
Cached Biology Technology:Oncothyreon Reports Third Quarter 2010 Financial Results 2Oncothyreon Reports Third Quarter 2010 Financial Results 3Oncothyreon Reports Third Quarter 2010 Financial Results 4Oncothyreon Reports Third Quarter 2010 Financial Results 5Oncothyreon Reports Third Quarter 2010 Financial Results 6Oncothyreon Reports Third Quarter 2010 Financial Results 7Oncothyreon Reports Third Quarter 2010 Financial Results 8Oncothyreon Reports Third Quarter 2010 Financial Results 9Oncothyreon Reports Third Quarter 2010 Financial Results 10Oncothyreon Reports Third Quarter 2010 Financial Results 11Kendle Announces Third Quarter 2010 Results 2Kendle Announces Third Quarter 2010 Results 3Kendle Announces Third Quarter 2010 Results 4Kendle Announces Third Quarter 2010 Results 5Kendle Announces Third Quarter 2010 Results 6HIPAA 5010 Ready: DST Health Solutions Launches Upgrades of Amisys Advance, PowerMHS, PowerMHC and PowerSTEPP 2HIPAA 5010 Ready: DST Health Solutions Launches Upgrades of Amisys Advance, PowerMHS, PowerMHC and PowerSTEPP 3
(Date:4/17/2015)... 17, 2015 Increasing ... technological advancement to drive biometric systems market in ...   According to a recently released ... &  Opportunities, 2020 ", biometric systems market in ... growth at CAGR of over 22% through 2020. ...
(Date:4/14/2015)... , April 14, 2015 NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... nominated for the 2015 New York Design Awards under ... Design100, New York City Design Awards are part of ... on over 2,500 ratings from the marketplace, industry and ...
(Date:4/13/2015)... 2015  higi, a leading cloud-based consumer engagement platform ... engage with their communities around health and wellness, announced ... secure API.  ... affordable, and convenient vehicle to receive validated health information ... The API will allow higi,s trusted partners, on ...
Breaking Biology News(10 mins):Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3
... Holdings, Inc. (NYSE MKT: ONVO) ("Organovo"), a three-dimensional biology company ... to present at the 24th Annual Oppenheimer Healthcare Conference, which ... December 10-11, 2013. Organovo,s Chairman and Chief ... Wednesday, December 11, at 2:45pm ET. The objective ...
... soak up a dangerous pore-forming toxin produced by MRSA ... safe and effective vaccine against this toxin. This "nanosponge ... the adverse effects of the alpha-haemolysin toxin from MRSAboth ... the University of California, San Diego described the safety ...
... proteins just beneath its surface until it is trapped as ... hits of energy eventually power the growth and movement of ... life. The three clumps of protein a light-harvesting ... look like random scrawls in illustrations but this is misleading. ...
Cached Biology News:Organovo to Present at the 24th Annual Oppenheimer Healthcare Conference 2'Nanosponge vaccine' fights MRSA toxins 2'Nanosponge vaccine' fights MRSA toxins 3'Nanosponge vaccine' fights MRSA toxins 4Scientists stitch up photosynthetic megacomplex 2Scientists stitch up photosynthetic megacomplex 3
Request Info...
Request Info...
Request Info...
... Ambion's custom siRNA service provides the ... gene silencing research. Custom siRNAs can be ... 19-21 base target sequence, or by providing ... check out Ambion's Silencer Validated and Silencer ...
Biology Products: